Investigational drug · Phase 3
TPST-1120
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Liver Cancers, Hepatocellular Carcinoma (HCC).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "TPST-1120"
First trial start
2020
Nov 1, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TPST-1120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Liver Cancers
- Hepatocellular Carcinoma (HCC)
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TPST-1120" as an intervention, largest first.
- A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyPivotal-lookingNot yet recruiting
Tempest TherapeuticsIndustry
NCT06680258 · 740 participants (planned) · Start Dec 2025 · Primary completion Dec 2028
Drug: TPST-1120; Atezolizumab and 1 more · For: Hepatocellular Carcinoma (HCC)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04524871 · 518 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 30, 2027
Drug: Atezolizumab; Bevacizumab 15 mg/kg and 11 more · For: Advanced Liver Cancers
Sites: Costa Mesa, California; Duarte, California; Orange, California · 32 sites in all
- TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersCompleted
Tempest TherapeuticsIndustry
NCT03829436 · 38 participants · Start Mar 20, 2019 · Primary completion Sep 7, 2022
Drug: Part 1 TPST-1120; Part 2 TPST-1120 + nivolumab and 2 more · For: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma and 9 more
Sites: San Francisco, California; Miami, Florida; Baltimore, Maryland · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- USP47 alleviates metabolic-associated fatty liver disease by activating the PPARα signaling pathway through the stabilization of SIRT1.
Cao Y, Wen Z, Chen J, et al. · Biochim Biophys Acta Mol Basis Dis 2026
- Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment.
Misal S, Patil VM, Ramaa CS, et al. · Bioorg Chem 2025
- First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Yarchoan M, Powderly JD, Bastos BR, et al. · Cancer Res Commun 2024
Also in development for Advanced Liver Cancers
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- RO7247669Tobemstomig, RG6139Phase 26 trials
Roche (Genentech) · Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer
- ADG126Phase 23 trials
Adagene Inc · Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers
- IO-108Phase 21 trial
Roche (Genentech) · Advanced Liver Cancers
- NKT2152Phase 21 trial
Roche (Genentech) · Advanced Liver Cancers
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.